BIT's 14th Annual Congress of International Drug Discovery Science & Technology 2016 Nov 16, 2016 20161116 Nov 19, 2016 Nanjing International Youth Conference Hotel, No.6 Yecheng Road, Nanjing, China The 14th Annual Congress of International Drug Discovery Science & Technology - 2016 (IDDST 2016) will be held during November 16-19, 2016 in Nanjing, China. With 7 supporting concurrent conferences in Medicinal Chemistry, Drug Delivery, Cancer Immunotherapy, Regenerative Medicine and Stem Cells, Mircobes and Modern Chinese Medicine, as well as a variety of social events, IDDST 2016 will attract more than 2000 participants from 80+ countries with over 500 posters and presentations on display. IDDST 2016 will arrange 100+ parallel sessions as well as a keynote forum. You can join the other 7 concurrent conferences free with one IDDST registration pass. /content/dam/pmiscience/default-fallback-thumbnails/conference/pmi-science-conference.png

      BIT's 14th Annual Congress of International Drug Discovery Science & Technology 2016

      Date
      Nov 16, 2016 - Nov 19, 2016
      Location
      Nanjing International Youth Conference Hotel, No.6 Yecheng Road, Nanjing, China
      The 14th Annual Congress of International Drug Discovery Science & Technology - 2016 (IDDST 2016) will be held during November 16-19, 2016 in Nanjing, China. With 7 supporting concurrent conferences in Medicinal Chemistry, Drug Delivery, Cancer Immunotherapy, Regenerative Medicine and Stem Cells, Mircobes and Modern Chinese Medicine, as well as a variety of social events, IDDST 2016 will attract more than 2000 participants from 80+ countries with over 500 posters and presentations on display. IDDST 2016 will arrange 100+ parallel sessions as well as a keynote forum. You can join the other 7 concurrent conferences free with one IDDST registration pass.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.